Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Net Income (2016 - 2025)

Ptc Therapeutics (PTCT) has 14 years of Net Income data on record, last reported at $414.1 million in Q4 2025.

  • For Q4 2025, Net Income fell 22.29% year-over-year to $414.1 million; the TTM value through Dec 2025 reached $1.2 billion, up 403.82%, while the annual FY2025 figure was $1.2 billion, 428.19% up from the prior year.
  • Net Income reached $414.1 million in Q4 2025 per PTCT's latest filing, up from -$23.1 million in the prior quarter.
  • Across five years, Net Income topped out at $866.6 million in Q1 2025 and bottomed at -$198.9 million in Q2 2023.
  • Average Net Income over 5 years is $14.0 million, with a median of -$113.8 million recorded in 2021.
  • Peak YoY movement for Net Income: plummeted 139.93% in 2023, then soared 1046.28% in 2025.
  • A 5-year view of Net Income shows it stood at -$137.7 million in 2021, then soared by 383.35% to $390.2 million in 2022, then tumbled by 139.93% to -$155.8 million in 2023, then surged by 442.07% to $532.9 million in 2024, then fell by 22.29% to $414.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Income were $414.1 million in Q4 2025, -$23.1 million in Q3 2025, and -$71.1 million in Q2 2025.